Vaccinex - About the company
Vaccinex is a deadpooled company based in United States, founded in 2021. It operates as a Developer of therapeutics for cancer and neurodegenerative diseases. The company has 3291 active competitors, including 1133 funded and 778 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.
Company Details
Developer of therapeutics for cancer and neurodegenerative diseases. The lead candidate Pepinemab is a humanized monoclonal IgG4 antibody that binds and blocks the signaling activity of SEMA4D that triggers neuroinflammation. It is used for the treatment of Huntington’s disease and non-small cell lung cancer. The company has ActivMAb fusion protein technology to develop therapeutics.
Key Metrics
Sign up to download Vaccinex's company profile
Vaccinex's funding and investors
Vaccinex has not raised any funding rounds yet.
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Vaccinex's Competitors and alternates
Top competitors of Vaccinex include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Vaccinex, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 80/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 75/100 | |
4th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
5th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 72/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 71/100 | |
9th | Karyopharm 2008, Newton (United States), Public | Biopharmaceutical company focused on developing and commercializing innovative cancer therapies | $98.4M | 71/100 | |
10th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 71/100 | ||
3780th |  Vaccinex 2021, United States, Deadpooled | Developer of therapeutics for cancer and neurodegenerative diseases | - | - | 15/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Vaccinex's competitors? Click here to see the top ones
Vaccinex's Investments and acquisitions
Vaccinex has made no investments or acquisitions yet.
Reports related to Vaccinex
Here is the latest report on Vaccinex's geography:
Are you a Founder ?
FAQs about Vaccinex
Explore our recently published companies
- FinLead AI - Delhi based, 2025 founded, Unfunded company
- Sylcloud - Unfunded company
- Ppbtechnology - 2017 founded, Unfunded company
- Opulancetechnologies - Unfunded company
- Starcgreen - Unfunded company
- World Wall - Overland Park based, 2016 founded, Unfunded company
